Lymphoblastic Leukemia Clinical Trial
— LeucosteoOfficial title:
Efficacy of Osteopathic Treatment on the Side Effects of Curative Treatments of Lymphoblastic Leukemia in Pediatrics
During the curative treatment of cancer, pain often remains the dominant symptom affecting the physical and psychological state of the patient. Osteopathy is an exclusively manual practice whose goal is to compensate for mobility dysfunctions of the tissues of the human body. It can be used as a complementary treatment for cancer pain when pain medications are not enough. The aim of this study is to examine the effectiveness of osteopathy in reducing pain intensity and improving quality of life in patients treated for pediatric acute lymphoblastic leukemia.
Status | Not yet recruiting |
Enrollment | 15 |
Est. completion date | August 1, 2023 |
Est. primary completion date | July 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Year to 10 Years |
Eligibility | Inclusion Criteria: - Patient managed and treated with a diagnosis of acute lymphoblastic leukemia - Patient between 1 and 10 years of age - Patient with pain at inclusion, or pain at diagnosis related to leukemia - Social security affiliation or entitlement - Signature of informed consent by both parents Exclusion Criteria: - No pain reported at the time of management or diagnosis - Surgery less than 30 days old - Patient with another contraindication to osteopathic treatment (worsening of the condition, bleeding syndrome), or a psychiatric pathology that prevents the scales from being used. |
Country | Name | City | State |
---|---|---|---|
France | Robert Debré Hospital | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluate the effectiveness of 5 weekly osteopathy sessions at regular intervals from week 1 to week 5 on the characteristics of the pain felt in patients aged 1 to 10 years treated for acute lymphoblastic leukemia using the HEDEN scale. | HEDEN (Hetero-Evaluation Pain Child) score before and after each intervention | 5 weeks | |
Secondary | Evaluate the effectiveness of 5 weekly osteopathy sessions at regular intervals from week 1 to week 5 on the intensity of the pain felt in patients aged 4 to 10 years treated for acute lymphoblastic leukemia using the face scale: FPS -R. | FPS-R (Face Pain Scale-Revised) score before and after each osteopathy session | 5 weeks | |
Secondary | To study the variations in quality of life at inclusion and at the end of the study using the PedsQL™ (questionnaire quality of life in paediatrics). | PedsQL™ Questionnaire quality of life in paediatrics | 5 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05043571 -
CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia
|
Phase 1 | |
Completed |
NCT00988013 -
Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies
|
N/A | |
Completed |
NCT00866749 -
Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
|
Phase 2 | |
Completed |
NCT01615809 -
Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia
|
Phase 2 | |
Recruiting |
NCT05993949 -
Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
|
Phase 1 | |
Recruiting |
NCT05848687 -
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
|
Phase 1/Phase 2 | |
Recruiting |
NCT05885464 -
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
|
Phase 1/Phase 2 | |
Terminated |
NCT01100658 -
Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors
|
N/A | |
Recruiting |
NCT05194397 -
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
|
Phase 2 | |
Completed |
NCT00388531 -
Depocyte in the Treatment of CNS Relapse in Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma
|
Phase 2 | |
Completed |
NCT00354120 -
Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant
|
Phase 2/Phase 3 | |
Recruiting |
NCT04747912 -
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
|
Phase 2 | |
Recruiting |
NCT05648019 -
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
|
Phase 2 | |
Completed |
NCT03328104 -
Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma
|
Phase 1 | |
Recruiting |
NCT05429905 -
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
|
Phase 1/Phase 2 | |
Terminated |
NCT00776373 -
Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT03564704 -
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
|
Phase 2/Phase 3 | |
Completed |
NCT04145531 -
An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06175702 -
Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL
|
||
Terminated |
NCT00967343 -
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
|
Phase 2/Phase 3 |